Humana (NYSE:HUM) Price Target Raised to $340.00 at Bank of America

Humana (NYSE:HUM) had its price target boosted by Bank of America from $267.00 to $340.00 in a research report issued on Thursday,Benzinga reports. The brokerage currently has a “neutral” rating on the insurance provider’s stock. Bank of America‘s price target suggests a potential downside of 2.66% from the company’s current price.

Several other research firms also recently issued reports on HUM. Weiss Ratings restated a “sell (d+)” rating on shares of Humana in a report on Tuesday, April 21st. Evercore increased their price target on shares of Humana from $195.00 to $250.00 in a report on Thursday, April 30th. Mizuho increased their price target on shares of Humana from $290.00 to $335.00 and gave the stock an “outperform” rating in a report on Wednesday, May 20th. Oppenheimer upgraded shares of Humana from an “outperform” rating to an “outperform” rating in a report on Wednesday, May 20th. Finally, Needham & Company LLC initiated coverage on shares of Humana in a report on Wednesday, May 20th. They issued a “buy” rating on the stock. Nine investment analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $279.30.

Humana Stock Up 6.6%

Shares of HUM traded up $21.74 during mid-day trading on Thursday, hitting $349.28. 995,402 shares of the company traded hands, compared to its average volume of 1,912,221. Humana has a 1-year low of $163.11 and a 1-year high of $351.76. The company has a quick ratio of 1.77, a current ratio of 1.77 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $41.93 billion, a PE ratio of 37.32, a price-to-earnings-growth ratio of 2.33 and a beta of 0.76. The business has a 50 day moving average of $241.36 and a 200 day moving average of $230.78.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, April 29th. The insurance provider reported $10.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $9.97 by $0.34. Humana had a net margin of 0.82% and a return on equity of 10.45%. The firm had revenue of $39.65 billion for the quarter, compared to the consensus estimate of $39.37 billion. During the same quarter in the prior year, the company posted $11.58 earnings per share. The company’s revenue for the quarter was up 23.5% compared to the same quarter last year. Humana has set its FY 2026 guidance at 9.000- EPS. Equities research analysts anticipate that Humana will post 9 EPS for the current year.

Institutional Investors Weigh In On Humana

Hedge funds and other institutional investors have recently made changes to their positions in the company. Montag A & Associates Inc. grew its stake in shares of Humana by 1,880.0% during the 4th quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider’s stock worth $25,000 after purchasing an additional 94 shares during the period. CoreCap Advisors LLC grew its stake in shares of Humana by 54.4% during the 4th quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider’s stock worth $27,000 after purchasing an additional 37 shares during the period. Fideuram Asset Management Ireland dac acquired a new stake in shares of Humana during the 4th quarter worth approximately $27,000. Reflection Asset Management acquired a new stake in shares of Humana during the 4th quarter worth approximately $29,000. Finally, Rosenberg Matthew Hamilton grew its stake in shares of Humana by 136.0% during the 4th quarter. Rosenberg Matthew Hamilton now owns 118 shares of the insurance provider’s stock worth $30,000 after purchasing an additional 68 shares during the period. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.